Oral Semaglutide and Fatty Liver: What a 28-Week Trial Shows

Oral semaglutide can produce substantial weight loss without diabetes, and a small randomized trial found liver-marker changes that look encouraging at first glance. The catch sits in the word marker. The study improved measures that can fall quickly when liver inflammation improves, but it did not show a significant change in two composite scores often used to estimate fibrosis risk.

That distinction matters for anyone reading a headline about a pill form of Ozempic or Wegovy "reversing liver scarring." The available evidence supports weight loss and suggests improved liver inflammation. It does not verify that oral semaglutide 14 mg reverses fibrotic collagen in the liver.

What the oral semaglutide trial found

In a 2025 randomized controlled trial by Katrevula et al., adults in India with overweight or obesity and no diabetes received dietary and physical-activity counseling. The treatment group also took oral semaglutide, titrated from 3 mg daily to 14 mg daily, while the control group received counseling alone. After 28 weeks, the semaglutide group had lost about 10.5% of body weight, a statistically significant result.

The trial also reported significant improvements in the AST-to-platelet ratio index (APRI) and liver stiffness measured by vibration-controlled transient elastography, often called FibroScan. Both results are relevant: obesity, liver fat, inflammation, and liver stiffness often move together. But the study found no statistically significant improvement in FIB-4 or the NAFLD Fibrosis Score (NFS).

Those four tests do not measure the same thing. APRI depends heavily on AST, a liver enzyme that often falls as inflammation improves. Elastography estimates stiffness, but stiffness can rise or fall because of inflammation, edema, and vascular congestion as well as collagen scarring. FIB-4 and NFS combine several variables and may change more slowly. None substitutes for a liver biopsy when the question is whether fibrosis stage itself has regressed.

The trial shows a real liver-related signal, but its pattern fits reduced inflammation better than confirmed fibrosis reversal.

Why weight loss may explain much of the liver benefit

Semaglutide's liver effects should not automatically be treated as direct proof of liver-specific drug action. In the 2025 STOP trial, investigators used serial cardiac CT scans in people with type 2 diabetes and found that reductions in liver fat tracked closely with the amount of weight lost on semaglutide.

Katrevula and colleagues did not include a weight-matched control group or a calorie-restricted comparison designed to separate drug effects from weight-loss effects. That leaves an important unanswered question: did oral semaglutide improve liver markers beyond what comparable weight loss would have done on its own? The trial cannot answer it.

This limitation does not make the result meaningless. Weight loss is one of the main treatments for metabolic fatty liver disease. It does mean that "semaglutide healed the liver" claims run ahead of the design.

The wider GLP-1 evidence: better inflammation than fibrosis proof

The broader literature points in the same direction. A 2025 systematic review and meta-analysis by Li et al. found that GLP-1 receptor agonists and related dual agonists consistently improved liver fat, lobular inflammation, hepatocellular ballooning, and imaging-based liver stiffness in metabolic dysfunction-associated steatohepatitis (MASH). Fibrosis-stage results were less consistent, especially outside higher-dose subcutaneous regimens.

A 2022 systematic review by Mantovani et al. reached a similar conclusion: GLP-1 receptor agonists reduced steatosis and elevated liver enzymes, while evidence for fibrosis-stage improvement remained variable. This is exactly why a lower APRI or a softer FibroScan reading cannot settle the fibrosis question.

Injectable semaglutide has been studied more deeply in liver disease than the oral pill. The ESSENCE phase 3 trial design paper describes a biopsy-based study of subcutaneous semaglutide 2.4 mg weekly in people with MASH and fibrosis stages F2 to F3. Its rationale includes earlier phase 2b data in 320 participants: subcutaneous semaglutide 0.4 mg daily produced MASH resolution in 59% of participants versus 17% with placebo, while fibrosis-stage improvement was not statistically significant.

That earlier result is useful perspective. Even with a higher-exposure injectable regimen and biopsy endpoints, improving inflammatory liver disease did not automatically produce a statistically significant fibrosis-stage result.

Why the pill-versus-shot question remains open

Oral semaglutide uses an absorption enhancer called SNAC to allow absorption through the stomach. Its systemic exposure is lower than with subcutaneous formulations, although this trial did not provide pharmacokinetic data that would permit a direct exposure comparison. Convenience is a legitimate reason to prefer a pill. It is not evidence that oral 14 mg provides the same liver exposure or anti-fibrotic effect as high-dose injectable semaglutide.

Other semaglutide studies add context but not a clean answer for people without diabetes. A 52-week real-world study by Volpe et al. reported improved fatty liver disease parameters with weekly subcutaneous semaglutide in people with type 2 diabetes. A 2023 cohort study by Carretero-Gómez et al. examined liver biomarkers after 24 weeks of weekly subcutaneous semaglutide in people with diabetes and obesity. Diabetes changes baseline insulin resistance and metabolic risk, so neither study directly validates the oral trial in non-diabetic obesity.

How much confidence should you place in the trial?

The Katrevula trial was randomized, which is a strength, but it was also open-label and conducted at a single tertiary center in India. Participants and investigators knew who received semaglutide. Because both groups received lifestyle counseling, the absence of blinding could affect adherence to diet and exercise and therefore magnify differences in weight and liver markers.

The 28-week follow-up is long enough to detect weight loss and changes in inflammation-sensitive measures. Fibrosis remodeling generally takes longer to establish, and the study did not use biopsy endpoints. Its results also may not generalize directly to North American or European populations, whose obesity patterns and metabolic risks can differ.

Most important, the trial contains its own restraint: APRI and elastography improved, while FIB-4 and NFS did not. Treating only the positive tests as the answer would turn a mixed result into a cleaner story than the data permit.

The practical verdict

For adults with obesity and fatty liver disease but no diabetes, oral semaglutide 14 mg daily has evidence from this 28-week trial for about 10.5% weight loss and for improvement in some noninvasive liver measures. Those changes are consistent with lower liver inflammation and with the weight-loss effects seen across the GLP-1 drug class.

It does not yet have evidence for biopsy-confirmed fibrosis reversal. If liver fibrosis is the reason for choosing treatment, a clinician should assess the actual stage of disease, review established lifestyle and medical options, and avoid using a lower liver-stiffness reading as proof that scar tissue has disappeared. The pill may help the metabolic conditions that drive fatty liver. The scarring claim still needs a trial built to prove it.